Summary & Overview
HCPCS J7345: Aminolevulinic Acid HCl 10% Topical Gel, 10 mg
HCPCS Level II code J7345 identifies aminolevulinic acid HCl 10% gel, 10 mg, a topical dermatologic pharmaceutical used in clinician-administered skin treatments. This code matters nationally because it standardizes reporting and billing for a distinct topical drug formulation that is used in procedural dermatology and related outpatient services. Accurate coding affects payer coverage determinations, claims processing, and aggregated utilization reporting across health systems.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for the medication, the typical service and site of service, and the implications for billing workflows. The publication highlights common modifiers associated with drug and service claims, notes the absence of payer-specific contractual details in the input, and outlines what types of benchmarks and policy updates would typically be relevant for this HCPCS Level II code.
This summary equips billing managers, dermatology clinicians, and policy stakeholders with the essential context to understand how J7345 is used in practice, what payers are typically involved at the national level, and what documentation and coding areas to review when this topical pharmaceutical is administered in outpatient settings.
Billing Code Overview
HCPCS Level II code J7345 represents aminolevulinic acid HCl for topical administration, 10% gel, 10 mg. The service is a topical pharmaceutical treatment formulated as a 10% gel containing 10 mg of the active ingredient administered for dermatologic indications. Typical site of service is outpatient dermatology clinics or physician offices, where topical therapies are applied in a clinical setting. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with multiple actinic keratoses on the face and scalp presents to a dermatology clinic for photodynamic therapy (PDT). The clinician selects Aminolevulinic acid HCl 10% gel (J7345) for topical application prior to activation with a blue or red light source. Typical workflow: patient check-in and consent; cleansing of treatment areas; selective lesion debridement or curettage as needed; application of Aminolevulinic acid HCl 10% gel to involved fields with protective measures for surrounding skin and eyes; an incubation period of approximately 1–3 hours under occlusion; subsequent illumination with an appropriate light source by trained staff; post-treatment cooling, application of topical emollient or sunscreen, and discharge instructions. The usual site of service is an outpatient dermatology clinic, ambulatory surgical center, or office-based procedure room. Typical patient scenario includes localized field treatment for actinic keratoses, superficial basal cell carcinoma clearance attempts, or acne in select cases where topical PDT is indicated. Reimbursement and documentation should include indication, area treated, amount of product used, incubation time, light source and settings, and any modifier(s) needed to reflect the professional or facility circumstance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|